News Releases
Sep 17, 2020
ALX Oncology Added to Russell 2000® and 3000® Indexes Read more
Sep 8, 2020
ALX Oncology Announces Participation at Upcoming Investor Conferences Read more
Aug 27, 2020
ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights Read more
Jul 21, 2020
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Read more
Jul 16, 2020
ALX Oncology Announces Pricing of Initial Public Offering Read more
Jun 12, 2020
ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Read more
May 29, 2020
ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors Read more
May 18, 2020
ALX Oncology to Present ALX148 Phase 1 Clinical Data at the Virtual 25th Congress of the European Hematology Association (EHA) Read more
May 14, 2020
ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Read more
May 4, 2020
ALX Oncology Announces Appointment of Rekha Hemrajani to Board of Directors Read more